Chapter 69 – Osteoporosis

[1]  M. Bouxsein,et al.  Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA‐HRpQCT Study , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  X. Guo,et al.  Lower Cortical Porosity and Higher Tissue Mineral Density in Chinese American Versus White Women , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  L. Melton,et al.  Trends in Fracture Incidence: A Population‐Based Study Over 20 Years , 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  Hang Lee,et al.  Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. , 2014, The Journal of clinical endocrinology and metabolism.

[5]  Cesar Libanati,et al.  Romosozumab in postmenopausal women with low bone mineral density , 2014, The New England journal of medicine.

[6]  I. Reid,et al.  Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis , 2014, The Lancet.

[7]  R. Chapurlat.  RETRACTED: Odanacatib for the treatment of postmenopausal osteoporosis , 2014, Expert opinion on pharmacotherapy.

[8]  L. Bonewald,et al.  Sclerostin Regulates Release of Bone Mineral by Osteocytes by Induction of Carbonic Anhydrase 2 , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  J. Eisman,et al.  Compound risk of high mortality following osteoporotic fracture and refracture in elderly women and men , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  Lewis H Kuller,et al.  Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. , 2013, JAMA.

[11]  Jacques P. Brown,et al.  The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension , 2013, The Journal of clinical endocrinology and metabolism.

[12]  Hang Lee,et al.  Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial , 2013, The Lancet.

[13]  Douglas P Kiel,et al.  Bone and Skeletal Muscle: Neighbors With Close Ties , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  F. Lugani,et al.  Osteocalcin regulates murine and human fertility through a pancreas-bone-testis axis. , 2013, The Journal of clinical investigation.

[15]  S. Manolagas.  Steroids and osteoporosis: the quest for mechanisms. , 2013, The Journal of clinical investigation.

[16]  J. Stevens,et al.  The impact of decreasing U.S. hip fracture rates on future hip fracture estimates , 2013, Osteoporosis International.

[17]  M. Bouxsein,et al.  The predictive value of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: an ex vivo study , 2013, Osteoporosis International.

[18]  I. Reid,et al.  Subgroup analysis for the risk of cardiovascular disease with calcium supplements , 2013, BoneKEy reports.

[19]  J. Eisman,et al.  Genetic profiling and individualized assessment of fracture risk , 2013, Nature Reviews Endocrinology.

[20]  Roland Baron,et al.  WNT signaling in bone homeostasis and disease: from human mutations to treatments , 2013, Nature Medicine.

[21]  J. Eisman,et al.  Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta-analysis , 2013, Osteoporosis International.

[22]  M. Almeida,et al.  Estrogen receptor-α signaling in osteoblast progenitors stimulates cortical bone accrual. , 2013, The Journal of clinical investigation.

[23]  H. Resch,et al.  Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  P. Delmas,et al.  A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data , 2012, Calcified Tissue International.

[25]  J. Reginster,et al.  Fracture risk and zoledronic acid therapy in men with osteoporosis. , 2012, The New England journal of medicine.

[26]  A. LaCroix,et al.  Differing risk profiles for individual fracture sites: Evidence from the global longitudinal study of osteoporosis in women (GLOW) , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[27]  W. Willett,et al.  A pooled analysis of vitamin D dose requirements for fracture prevention. , 2012, The New England journal of medicine.

[28]  L. Lix,et al.  A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving , 2012, Osteoporosis International.

[29]  C. Cooper,et al.  A systematic review of hip fracture incidence and probability of fracture worldwide , 2012, Osteoporosis International.

[30]  S. Cummings,et al.  Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures , 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  G. Karsenty,et al.  The contribution of bone to whole-organism physiology , 2012, Nature.

[32]  G. Baron,et al.  Influence of vertebral fracture assessment by dual-energy X-ray absorptiometry on decision-making in osteoporosis: a structured vignette survey. , 2011, Rheumatology.

[33]  M. Almeida,et al.  Glucocorticoids and Tumor Necrosis Factor α Increase Oxidative Stress and Suppress Wnt Protein Signaling in Osteoblasts* , 2011, The Journal of Biological Chemistry.

[34]  A. Wolk,et al.  Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study , 2011, BMJ : British Medical Journal.

[35]  P. Delmas,et al.  Finite element analysis performed on radius and tibia HR‐pQCT images and fragility fractures at all sites in men , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[36]  S. Cummings,et al.  Secular trends in the incidence of hip and other osteoporotic fractures , 2011, Osteoporosis International.

[37]  René Rizzoli,et al.  Effect of music-based multitask training on gait, balance, and fall risk in elderly people: a randomized controlled trial. , 2011, Archives of internal medicine.

[38]  S. Boonen,et al.  Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[39]  Heather M. Macdonald,et al.  Age‐related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: A population‐based HR‐pQCT study , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[40]  A. Avenell,et al.  Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis , 2010, BMJ : British Medical Journal.

[41]  Hang Lee,et al.  Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. , 2010, The Journal of clinical endocrinology and metabolism.

[42]  Bert Van Rietbergen,et al.  Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in postmenopausal women. , 2010, Bone.

[43]  I. Reid,et al.  Effect of osteoporosis treatment on mortality: a meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.

[44]  Claus Christiansen,et al.  Denosumab for prevention of fractures in postmenopausal women with osteoporosis. , 2009, The New England journal of medicine.

[45]  E. Seeman,et al.  Differences in Macro‐ and Microarchitecture of the Appendicular Skeleton in Young Chinese and White Women , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[46]  J. Reginster,et al.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial , 2009, The Lancet.

[47]  J. Eisman,et al.  Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. , 2009, JAMA.

[48]  B. van Rietbergen,et al.  Bone micro-architecture and determinants of strength in the radius and tibia: age-related changes in a population-based study of normal adults measured with high-resolution pQCT , 2009, Osteoporosis International.

[49]  Jacques P. Brown,et al.  Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  Claus Christiansen,et al.  Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3‐Year, Randomized, Placebo‐, and Active‐Controlled Clinical Trial , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  R. Chlebowski,et al.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  S. Boonen,et al.  Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. , 2008, The Journal of clinical endocrinology and metabolism.

[53]  S. Boonen,et al.  Effects of Two Years of Daily Teriparatide Treatment on BMD in Postmenopausal Women With Severe Osteoporosis With and Without Prior Antiresorptive Treatment , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[54]  Richard S. Rosenthal,et al.  The effect of thiazolidinediones on BMD and osteoporosis , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[55]  J. Kanis,et al.  Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.

[56]  M. Kumle.  Declining breast cancer incidence and decreased HRT use , 2008, The Lancet.

[57]  S. Cummings,et al.  The effects of tibolone in older postmenopausal women. , 2008, The New England journal of medicine.

[58]  J. S. San Martin,et al.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. , 2008, Bone.

[59]  J. Eisman,et al.  Association between LRP5 polymorphism and bone mineral density: a Bayesian meta-analysis , 2008, BMC Medical Genetics.

[60]  A Hofman,et al.  Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study , 2008, The Lancet.

[61]  A. LaCroix,et al.  Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[62]  A. Uitterlinden,et al.  Large-scale analysis of association between polymorphisms in the transforming growth factor beta 1 gene (TGFB1) and osteoporosis: the GENOMOS study. , 2008, Bone.

[63]  D. Kiel,et al.  Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. , 2008, JAMA.

[64]  M. Beckmann,et al.  Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  L. Melton,et al.  Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA , 2008, Osteoporosis International.

[66]  L. Melton,et al.  Cost-effective osteoporosis treatment thresholds: the United States perspective , 2008, Osteoporosis International.

[67]  I. Reid,et al.  Effect of calcium supplementation on hip fractures , 2008, Osteoporosis International.

[68]  C. Cooper,et al.  Intrauterine programming of bone. Part 2: Alteration of skeletal structure , 2008, Osteoporosis International.

[69]  C. Cooper,et al.  Intrauterine programming of bone. Part 1: Alteration of the osteogenic environment , 2008, Osteoporosis International.

[70]  Bert Van Rietbergen,et al.  Finite Element Analysis Based on In Vivo HR‐pQCT Images of the Distal Radius Is Associated With Wrist Fracture in Postmenopausal Women , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[71]  S. Boonen,et al.  Zoledronic acid and clinical fractures and mortality after hip fracture. , 2007, The New England journal of medicine.

[72]  Richard A Robb,et al.  A Population‐Based Assessment of Rates of Bone Loss at Multiple Skeletal Sites: Evidence for Substantial Trabecular Bone Loss in Young Adult Women and Men , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[73]  Alan Bensoussan,et al.  Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis , 2007, The Lancet.

[74]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[75]  S. Cummings,et al.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. , 2007, The New England journal of medicine.

[76]  J. Manson,et al.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. , 2007, JAMA.

[77]  Richard Eastell,et al.  Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. , 2007, The Journal of clinical endocrinology and metabolism.

[78]  E. Seeman,et al.  Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. , 2007, Endocrine reviews.

[79]  R. Lindsay,et al.  Effect of Recombinant Human Parathyroid Hormone (1-84) on Vertebral Fracture and Bone Mineral Density in Postmenopausal Women with Osteoporosis , 2007, Annals of Internal Medicine.

[80]  P. Delmas,et al.  Alterations of Cortical and Trabecular Architecture Are Associated With Fractures in Postmenopausal Women, Partially Independent of Decreased BMD Measured by DXA: The OFELY Study , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[81]  A. Tosteson,et al.  Incidence and Economic Burden of Osteoporosis‐Related Fractures in the United States, 2005–2025 , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[82]  E. Barrett-Connor,et al.  Adult Weight Change and Risk of Postmenopausal Breast Cancer , 2006, The New England journal of medicine.

[83]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[84]  F. Duboeuf,et al.  Effectiveness of instant vertebral assessment to detect prevalent vertebral fracture , 2006, Osteoporosis International.

[85]  P. Delmas,et al.  Bone quality--the material and structural basis of bone strength and fragility. , 2006, The New England journal of medicine.

[86]  P. Delmas,et al.  Drug Insight: bisphosphonates for postmenopausal osteoporosis , 2006, Nature Clinical Practice Endocrinology &Metabolism.

[87]  M. Bouxsein,et al.  In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. , 2005, The Journal of clinical endocrinology and metabolism.

[88]  Ann L Oberg,et al.  Effects of Sex and Age on Bone Microstructure at the Ultradistal Radius: A Population‐Based Noninvasive In Vivo Assessment , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[89]  D. Fyhrie,et al.  The morphological association between microcracks and osteocyte lacunae in human cortical bone. , 2005, Bone.

[90]  S. Cummings,et al.  Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial , 2005, Osteoporosis International.

[91]  E. Lewiecki,et al.  Early Changes in Biochemical Markers of Bone Formation Predict BMD Response to Teriparatide in Postmenopausal Women With Osteoporosis , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[92]  S. Cummings,et al.  Clinical utility of laboratory testing in women with osteoporosis , 2005, Osteoporosis International.

[93]  C. Cooper,et al.  A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. , 2005, QJM : monthly journal of the Association of Physicians.

[94]  Sundeep Khosla,et al.  Population‐Based Study of Age and Sex Differences in Bone Volumetric Density, Size, Geometry, and Structure at Different Skeletal Sites , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[95]  O Johnell,et al.  A family history of fracture and fracture risk: a meta-analysis. , 2004, Bone.

[96]  O Johnell,et al.  A meta-analysis of previous fracture and subsequent fracture risk. , 2004, Bone.

[97]  C. Christiansen,et al.  Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[98]  D. Bauer,et al.  Change in Bone Turnover and Hip, Non‐Spine, and Vertebral Fracture in Alendronate‐Treated Women: The Fracture Intervention Trial , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[99]  B. Ettinger,et al.  Differential Effects of Teriparatide on BMD After Treatment With Raloxifene or Alendronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[100]  C. Cooper,et al.  Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. , 2003, Arthritis and rheumatism.

[101]  A. LaCroix,et al.  Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.

[102]  J. Finkelstein,et al.  The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.

[103]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[104]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[105]  Oscar L. Sierra,et al.  Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-γ-induced class II transactivator , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Mary Cushman,et al.  Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.

[107]  E. Seeman.  Periosteal bone formation--a neglected determinant of bone strength. , 2003, The New England journal of medicine.

[108]  O. Johnell,et al.  Bone loss and bone size after menopause. , 2003, The New England journal of medicine.

[109]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[110]  R. Eastell,et al.  Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[111]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[112]  C. Kooperberg,et al.  Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. , 2003, JAMA.

[113]  J. Manson,et al.  Effects of estrogen plus progestin on health-related quality of life. , 2003, The New England journal of medicine.

[114]  Lex M Bouter,et al.  Prevention of hip fractures by external hip protectors: a randomized controlled trial. , 2003, JAMA.

[115]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[116]  D. C. Bauer,et al.  Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures , 2003, Osteoporosis International.

[117]  A. Parfitt,et al.  Reversal of Bone Loss in Mice by Nongenotropic Signaling of Sex Steroids , 2002, Science.

[118]  C. Cooper,et al.  The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysis , 2002, Osteoporosis International.

[119]  D. Meier,et al.  Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. , 2002, The Journal of clinical endocrinology and metabolism.

[120]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[121]  J Dequeker,et al.  Incidence of Vertebral Fracture in Europe: Results From the European Prospective Osteoporosis Study (EPOS) , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[122]  Fran Harris,et al.  Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. , 2002, The American journal of medicine.

[123]  Jacques P. Brown,et al.  Intravenous zoledronic acid in postmenopausal women with low bone mineral density. , 2002, The New England journal of medicine.

[124]  O. Johnell,et al.  Ten Year Probabilities of Osteoporotic Fractures According to BMD and Diagnostic Thresholds , 2001, Osteoporosis International.

[125]  D. Torgerson,et al.  Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials , 2001, BMC musculoskeletal disorders.

[126]  G. Fitzmaurice,et al.  Effects of inhaled glucocorticoids on bone density in premenopausal women. , 2001, The New England journal of medicine.

[127]  J. Ioannidis,et al.  Association of Collagen Iα 1 Sp1 Polymorphism with the Risk of Prevalent Fractures: A Meta‐Analysis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[128]  D. Torgerson,et al.  Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. , 2001, JAMA.

[129]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[130]  B. Manthey,et al.  Intervertebral Disc Disorganization Is Related to Trabecular Bone Architecture in the Lumbar Spine , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[131]  J A Kanis,et al.  Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis. , 2001, Bone.

[132]  P Geusens,et al.  Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. , 2001, The New England journal of medicine.

[133]  P Geusens,et al.  Risk of new vertebral fracture in the year following a fracture. , 2001, JAMA.

[134]  P Kannus,et al.  Prevention of hip fracture in elderly people with use of a hip protector. , 2000, The New England journal of medicine.

[135]  I. Reid,et al.  Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. , 2000, The American journal of medicine.

[136]  D. Reid,et al.  Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy , 2000, Calcified Tissue International.

[137]  P. Delmas,et al.  Serum Estradiol and Sex Hormone‐Binding Globulin and the Risk of Hip Fracture in Elderly Women: The EPIDOS Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[138]  P. Delmas,et al.  Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study. , 2000, Bone.

[139]  J. Pike,et al.  Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[140]  T. Abbott,et al.  Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of the Literature and Statistical Synthesis , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[141]  E. Siris,et al.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. , 1999, The New England journal of medicine.

[142]  D. Lacey,et al.  Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. , 1999, Endocrinology.

[143]  S. Cummings,et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. , 1999, JAMA.

[144]  H K Genant,et al.  Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. , 1999, Archives of internal medicine.

[145]  J. Eisman,et al.  Mortality after all major types of osteoporotic fracture in men and women: an observational study , 1999, The Lancet.

[146]  A. LaCroix,et al.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. , 1998, JAMA.

[147]  S. Cummings,et al.  Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. , 1998, The New England journal of medicine.

[148]  J. Bilezikian,et al.  Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. , 1998, The New England journal of medicine.

[149]  E. Vittinghoff,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[150]  Jacques P. Brown,et al.  Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis , 1998 .

[151]  S. Cummings,et al.  The Association of Radiographically Detected Vertebral Fractures with Back Pain and Function: A Prospective Study , 1998, Annals of Internal Medicine.

[152]  B. L. Riggs,et al.  A Unitary Model for Involutional Osteoporosis: Estrogen Deficiency Causes Both Type I and Type II Osteoporosis in Postmenopausal Women and Contributes to Bone Loss in Aging Men , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[153]  G Pearce,et al.  Exercise Before Puberty May Confer Residual Benefits in Bone Density in Adulthood: Studies in Active Prepubertal and Retired Female Gymnasts , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[154]  C. Christiansen,et al.  Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. , 1998 .

[155]  E. Barrett-Connor,et al.  Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. , 1997, Archives of internal medicine.

[156]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[157]  M. Barker,et al.  Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial , 1997, BMJ.

[158]  D. Hans,et al.  Different Morphometric and Densitometric Parameters Predict Cervical and Trochanteric Hip Fracture: The EPIDOS Study , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[159]  G E Dallal,et al.  Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. , 1997, The New England journal of medicine.

[160]  J. Eisman,et al.  Prediction of bone density from vitamin D raceptor alleles , 1997, nature.

[161]  R. Rizzoli,et al.  Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. , 1997, The Journal of clinical investigation.

[162]  L. Melton,et al.  Medical Expenditures for the Treatment of Osteoporotic Fractures in the United States in 1995: Report from the National Osteoporosis Foundation , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[163]  S. Cummings,et al.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures , 1996, The Lancet.

[164]  C Marcelli,et al.  Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[165]  G. Breart,et al.  Fall-related factors and risk of hip fracture: the EPIDOS prospective study , 1996, The Lancet.

[166]  A. Silman,et al.  The prevalence of vertebral deformity in European men and women: The european vertebral osteoporosis study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[167]  C. Christiansen,et al.  Low bone mass and fast rate of bone loss at menopause: Equal risk factors for future fracture: A 15-year follow-up Study , 1996 .

[168]  P. Delmas,et al.  Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: The OFELY study , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[169]  S. Wolf,et al.  Reducing Frailty and Falls in Older Persons: An Investigation of Tai Chi and Computerized Balance Training , 1996, Journal of the American Geriatrics Society.

[170]  P. Delmas,et al.  Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[171]  L. Bouter,et al.  Vitamin D Supplementation and Fracture Incidence in Elderly Persons , 1996, Annals of Internal Medicine.

[172]  K. Bose,et al.  Effect of femoral rotation on bone mineral density measurements with dual energy X-ray absorptiometry , 1995, Calcified Tissue International.

[173]  O. Johnell,et al.  Risk factors for hip fracture in european women: The MEDOS study , 1995 .

[174]  L. Mosekilde,et al.  Osteoporosis and exercise. , 1995, Bone.

[175]  M. Peacock.  Vitamin D receptor gene alleles and osteoporosis: A contrasting view , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[176]  S. Cummings,et al.  Estrogen Replacement Therapy and Fractures in Older Women , 1995, Annals of Internal Medicine.

[177]  Ari Heinonen,et al.  Effect of Starting Age of Physical Activity on Bone Mass in the Dominant Arm of Tennis and Squash Players , 1995, Annals of Internal Medicine.

[178]  P. Delmas,et al.  The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate--is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? , 1995, Bone.

[179]  S. Cummings,et al.  Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. , 1995, The New England journal of medicine.

[180]  R. Harba,et al.  Fractal organization of trabecular bone images on calcaneus radiographs , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[181]  I. Reid,et al.  Relation between increase in length of hip axis in older women between 1950s and 1990s and increase in age specific rates of hip fracture , 1994, BMJ.

[182]  E. Fisher,et al.  RACIAL DIFFERENCES IN FRACTURE RISK , 1994, Epidemiology.

[183]  S. Cummings,et al.  TYPE OF FALL AND RISK OF HIP AND WRIST FRACTURES: THE STUDY OF OSTEOPOROTIC FRACTURES , 1993, Journal of the American Geriatrics Society.

[184]  C C Glüer,et al.  Simple measurement of femoral geometry predicts hip fracture: The study of osteoporotic fractures , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[185]  M. Nevitt,et al.  Vertebral fracture assessment using a semiquantitative technique , 1993, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[186]  C. Cooper,et al.  Prevalence and incidence of vertebral deformities , 1993, Osteoporosis International.

[187]  T. Spector,et al.  The assessment of vertebral deformity: A method for use in population studies and clinical trials , 1993, Osteoporosis International.

[188]  C. Cooper,et al.  Population-based study of survival after osteoporotic fractures. , 1993, American journal of epidemiology.

[189]  S. Cummings,et al.  Factors Associated with Appendicular Bone Mass in Older Women , 1993, Annals of Internal Medicine.

[190]  S. Cummings,et al.  Bone density at various sites for prediction of hip fractures , 1993, The Lancet.

[191]  F Duboeuf,et al.  Vitamin D3 and calcium to prevent hip fractures in elderly women. , 1992, The New England journal of medicine.

[192]  S. Nozawa,et al.  Which is more osteoporosis-inducing, menopause or oophorectomy? , 1992, Bone and mineral.

[193]  E. Orwoll,et al.  Vertebral deformity in men , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[194]  E. Harju,et al.  Annual injection of vitamin D and fractures of aged bones , 1992, Calcified Tissue International.

[195]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[196]  C. Slemenda,et al.  Calcium supplementation and increases in bone mineral density in children. , 1992, The New England journal of medicine.

[197]  C. Cooper,et al.  Incidence of clinically diagnosed vertebral fractures: A population‐based study in rochester, minnesota, 1985‐1989 , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[198]  B. Riis,et al.  Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. , 1991, BMJ.

[199]  P. Marie,et al.  Decreased DNA synthesis by cultured osteoblastic cells in eugonadal osteoporotic men with defective bone formation. , 1991, The Journal of clinical investigation.

[200]  L. Sokoll,et al.  Effect of vitamin D supplementation on wintertime and overall bone loss in healthy postmenopausal women. , 1991, Annals of internal medicine.

[201]  P. Padfield,et al.  Inhaled corticosteroids, bone formation, and osteocalcin , 1991, The Lancet.

[202]  M. Kleerekoper,et al.  Structural and geometric changes in iliac bone: Relationship to normal aging and osteoporosis , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[203]  I. Reid,et al.  The influence of osteophytes and aortic calcification on spinal mineral density in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.

[204]  J. Prior,et al.  Spinal bone loss and ovulatory disturbances , 1990, The New England journal of medicine.

[205]  M. Hall,et al.  Bone mineral loss in young women with amenorrhoea. , 1990 .

[206]  Y. Sahlin.  Occurrence of fractures in a defined population: a 1-year study. , 1990, Injury.

[207]  C. Cooper,et al.  Physical activity, muscle strength, and calcium intake in fracture of the proximal femur in Britain. , 1988, BMJ.

[208]  J. Gallagher,et al.  Vertebral morphometry in diagnosis of spinal fractures. , 1988, Bone and mineral.

[209]  W. Crowley,et al.  Osteoporosis in Men with Idiopathic Hypogonadotropic Hypogonadism , 1987 .

[210]  S. Toh,et al.  Effect of hyperthyroidism and its treatment on bone mineral content. , 1985, Archives of internal medicine.

[211]  M. Kleerekoper,et al.  Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. , 1983, The Journal of clinical investigation.

[212]  B. Riggs,et al.  Incidence of Colles' fracture in a North American community. , 1982, American journal of public health.

[213]  R. Lindsay,et al.  PREVENTION OF SPINAL OSTEOPOROSIS IN OOPHORECTOMISED WOMEN , 1980, The Lancet.

[214]  J. Christian,et al.  Genetic factors in determining bone mass. , 1973, The Journal of clinical investigation.

[215]  D. Hans,et al.  Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study , 2012, Osteoporosis International.

[216]  C. Wu,et al.  Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures , 2005, Osteoporosis International.

[217]  M. Jergas,et al.  Accurate assessment of precision errors: How to measure the reproducibility of bone densitometry techniques , 2005, Osteoporosis International.

[218]  M. Kleerekoper,et al.  Vertebral fracture or vertebral deformity? , 2004, Calcified Tissue International.

[219]  R. Harwood,et al.  A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study. , 2004, Age and ageing.

[220]  O. Johnell,et al.  Uncertain Future of Trials in Osteoporosis , 2002, Osteoporosis International.

[221]  C. Christiansen,et al.  Six and Twelve Month Changes in Bone Turnover are Related to Reduction in Vertebral Fracture Risk During 3 Years of Raloxifene Treatment in Postmenopausal Osteoporosis , 2001, Osteoporosis International.

[222]  E. Orwoll,et al.  Does Bone Density Predict Fractures Comparably in Men and Women? , 2001, Osteoporosis International.

[223]  O. Johnell,et al.  The Burden of Osteoporotic Fractures: A Method for Setting Intervention Thresholds , 2001, Osteoporosis International.

[224]  P. Delmas,et al.  Biochemical Measurements of Bone Turnover in Children and Adolescents , 2000, Osteoporosis International.

[225]  M. Hooper,et al.  Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis , 2000, Osteoporosis International.

[226]  P. Delmas,et al.  Longitudinal Study of Bone Loss in Pre- and Perimenopausal Women: Evidence for Bone Loss in Perimenopausal Women , 2000, Osteoporosis International.

[227]  D. Hans,et al.  Do Markers of Bone Resorption Add to Bone Mineral Density and Ultrasonographic Heel Measurement for the Prediction of Hip Fracture in Elderly Women? The EPIDOS Prospective Study , 1998, Osteoporosis International.

[228]  S. Bentzen,et al.  The predictive value of quantitative computed tomography for vertebral body compressive strength and ash density. , 1989, Bone.

[229]  J L Kelsey,et al.  Epidemiology of osteoporosis and osteoporotic fractures. , 1985, Epidemiologic reviews.

[230]  J. Jensen,et al.  Long-term social prognosis after hip fractures. , 1982, Acta orthopaedica Scandinavica.